Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity

Cancer Research

Volumn 68, Issue 7, 2008, Pages 2400-2408

  Li, Bohua ^a,b   Shi, Shu ^a   Qian, Weizhu ^a,b   Zhao, Lei ^a   Zhang, Dapeng ^a   Hou, Sheng ^a,b   Zheng, Lei ^a   Dai, Jianxin ^a   Zhao, Jian ^a   Wang, Hao ^a,b   Guo, Yajun ^a,b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Shanghai Center for Cell Engineering and Antibody   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2F2; MONOCLONAL ANTIBODY C2B8; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; B CELL LYMPHOMA; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; FEMALE; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD30; ANTINEOPLASTIC AGENTS; BURKITT LYMPHOMA; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL; MICE; MICE, INBRED BALB C; MICE, INBRED ICR; MICE, SCID; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 42049085694     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6663     Document Type: Article

References (43)

1. Tedder TF, Streuli M, Schlossman SF, Saito H. Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. Proc Natl Acad Sci U S A 1988;85:208-12.
2. Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994;15:450-4.
3. Maloney DG. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. J Clin Oncol 2005;23:6421-8.
4. Glennie MJ, van de Winkel JG. Renaissance of cancer therapeutic antibodies. Drug Discov Today 2003;8:503-10.
5. Leget GA, Czuczman MS. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol 1998;10:548-51.
6. Sharkey RM, Goldenberg DM. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin 2006;56:226-43.
7. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33.
8. Maloney DG, Grillo-López AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997;15:3266-74.
9. Eisenbeis CF, Caligiuri MA, Byrd JC. Rituximab: converging mechanisms of action in non-Hodgkin's lymphoma? Clin Cancer Res 2003;9:5810-2.
10. Ghetie MA, Bright H, Vitetta ES. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood 2001;97:1392-8.
11. Zhang N, Khawli LA, Hu P, Epstein AL. Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphomas. Clin Cancer Res 2005;11:5971-80.
12. Iida S, Misaka H, Inoue M, et al. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcγRIIIa. Clin Cancer Res 2006;12:2879-87.
13. Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004;104:1793-800.
14. Nishida M, Usuda S, Okabe M, et al. Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab). Int J Oncol 2007;31:29-40.
15. Cragg MS, Morgan SM, Chan HT, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003;101:1045-52.
16. Chan HT, Hughes D, French RR, et al. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res 2003;63:5480-89.
17. Davis T, Kamiski M, Leonard J, Gregory S. Results of a randomized study of Bexxar (Tositumomab and I 131 Tositumomab) vs unlabeled Tositumomab in patients with relapsed or refractory low-grade or transformed non-Hodgkin's lymphoma [abstract]. Blood 2001;98:843a.
18. 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts. Cancer Res 1992;52:6476-81.
19. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45.
20. Meng R, Smallshaw JE, Pop LM, et al. The evaluation of recombinant, chimeric, tetravalent antihuman CD22 antibodies. Clin Cancer Res 2004;10:1274-81.
21. Liu XY, Pop LM, Roopenian DC, Ghetie V, Vitetta ES, Smallshaw JE. Generation and characterization of a novel tetravalent anti-CD22 antibody with improved antitumor activity and pharmacokinetics. Int Immunopharmacol 2006;6:791-9.
22. Li B, Wang H, Dai J, et al. Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions. Immunology 2005;116:487-98.
23. Looney RJ, Abraham GN, Anderson CL. Human monocytes and U937 cells bear two distinct Fc receptors for IgG. J Immunol 1986;136:1641-7.
24. Jones DH, Looney RJ, Anderson CL. Two distinct classes of IgG Fc receptors on a human monocyte line (U937) defined by differences in binding of murine IgG subclasses at low ionic strength. J Immunol 1985;135:3348-53.
25. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
26. Rebello P, Hale G. Pharmacokinetics of CAMPATH-1H: assay development and validation. J Immunol Methods 2002;260:285-302.
27. Wolff EA, Schreiber GJ, Cosand WL, Raff HV. Monoclonal antibody homodimers: enhanced antitumor activity in nude mice. Cancer Res 1993;53:2560-5.
28. Ghetie MA, Podar EM, Ilgen A, Gordon BE, Uhr JW, Vitetta ES. Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. Proc Natl Acad Sci U S A 1997;94:7509-14.
29. Clark EA, Ledbetter JA. How does B cell depletion therapy work, and how can it be improved? Ann Rheum Dis 2005;64:77-80.
30. Bannerji R, Kitada S, Flinn IW, et al. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. J Clin Oncol 2003;21:1466-71.
31. Byrd JC, Smith L, Hackbarth ML, et al. Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. Cancer Res 2003;63:36-8.
32. Bezombes C, Grazide S, Garret C, et al. Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood 2004;104:1166-73.
33. van der Kolk LE, Grillo-Lopez AJ, Baars JW, Hack CE, van Oers MH. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 2001;115:807-11.
34. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999;94:2217-24.
35. Treon SP, Mitsiades C, Mitsiades N, et al. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother 2001;24:263-71.
36. Bannerji RPM, Flinn IW. Cell surface complement inhibitors CD55 and CD59 may mediate chronic lymphocytic leukemia (CLL) resistance to rituximab therapy [abstract]. Blood 2000;96:164.
37. Polyak MJ, Tailor SH, Deans JP. Identification of a cytoplasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment. J Immunol 1998;161:3242-8.
38. Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006;177:362-71.
39. Polyak MJ, Deans JP. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood 2002;99:3256-62.
40. Perosa F, Favoino E, Caragnano MA, Dammacco F. Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor. Blood 2006;107:1070-7.
41. Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M. The epitope recognized by rituximab. Blood 2006;108:1975-8.
42. Du J, Wang H, Zhong C, et al. Structural basis for recognition of CD20 by therapeutic antibody Rituximab. J Biol Chem 2007;282:15073-80.
43. Mohrbacher A. B cell non-Hodgkin's lymphoma: rituximab safety experience. Arthritis Res Ther 2005;7 Suppl 3:S19-25.